Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Kumar L, Verma S, Singh M, Chalotra T, Utreja P
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
Notably, there was no change in plasma of the precursor PAA (Supplementary Fig
This molecule is now being evaluated in a phase 2 clinical trial on MS patients
CAT No: 10-101-343 CAS No: 1401708-83-5 Synonyms/Alias: dihexa;1401708-83-5;L-Isoleucinamide, N-(1-oxohexyl)-L-tyrosyl-N-(6-amino-6-oxohexyl)-;N-hexanoic-Tyr-Ile-(6) aminohexanoic amide;9WYX65A5C2;PNB-0408;(2S,3S)-N-(6-amino-6-oxohexyl)-2-[[(2S)-2-(hexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanamide;6-(2-(2-Hexanamido-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)hexanamide;6-[(2S,3S)-2-[(2S)-2-hexanamido-3-(4-hydroxyphenyl)propanamido]-3-methylpentanamido]hexanamide;Hexanoyl-Tyr-Ile-Ahx-NH2;UNII-9WYX65A5C2;Dihexa (PNB-0408)?;DTXSID701032895;GLXC-25923;ATH-1001;AKOS040759118;CS-6864;DA-62870;HY-16969;PNB-0408
Our experienced medical team recommends Sermorelin for many patients because it offers a favorable safety profile compared to other growth hormone-releasing peptides (GHRPs) such as Ipamorelin, GHRP-2, and GHRP-6
US$ 20.93
US$ 29.15
US$ 21.82
US$ 28.69
